Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Forge Announces Visible Gold & Continued Porphyry Mineralization at Alotta Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ensysce Biosciences Inc ENSC

Alternate Symbol(s):  ENSCW

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology... see more

Recent & Breaking News (NDAQ:ENSC)

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

ACCESS Newswire 7 days ago

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

ACCESS Newswire June 4, 2025

Ensysce Biosciences Reports First Quarter 2025 Financial Results

ACCESS Newswire May 13, 2025

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

ACCESS Newswire May 12, 2025

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

ACCESS Newswire April 24, 2025

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

ACCESS Newswire April 23, 2025

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

ACCESS Newswire April 23, 2025

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

ACCESS Newswire April 15, 2025

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESS Newswire March 31, 2025

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

ACCESS Newswire March 18, 2025

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

ACCESS Newswire March 10, 2025

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

ACCESS Newswire March 5, 2025

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

PR Newswire March 3, 2025

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

ACCESS Newswire February 5, 2025

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

ACCESS Newswire January 22, 2025

Ensysce Biosciences Issues Annual Shareholder Letter

ACCESS Newswire January 8, 2025

Ensysce Biosciences Regains Full Compliance with Nasdaq

ACCESS Newswire December 23, 2024

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

ACCESS Newswire December 10, 2024

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

ACCESS Newswire December 4, 2024

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

ACCESS Newswire December 3, 2024